Acne Research Today is a free monthly online journal that collates and summarizes the latest research about Acne, including details on skin problems, diet, treatments, puberty.

Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy.

Franks S, Layton A, Glasier A

Reproductive Endocrinology, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital, London W12 0NN, UK. s.franks@imperial.ac.uk

Clinical manifestations of androgen excess-hirsutism, acne and alopecia-are very common and distressing symptoms in women of reproductive age. These symptoms are frequently associated with polycystic ovary syndrome, in which condition menstrual disturbances are also common. The combination of the anti-androgen cyproterone acetate (2 mg) and ethinyl estradiol (35 microg) (co-cypridiol) is of proven efficacy in management of symptoms of both hyperandrogenism and menstrual abnormalities but its long-term use has been discouraged because of concern about increased risk of venous thromboembolism. In this article, we review the evidence for efficacy and adverse effects and conclude that its benefits are clear and that the risks of venous thromboembolism are no more common that with the use of third generation combined oral contraceptives.

Published 17 January 2008 in Hum Reprod, 23(2): 231-2.
Full-text of this article is available online (may require subscription).

© 2004-2008 Acne Research Today. All Rights Reserved.